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Abstract:  A  major  virulence  factor  of  Bacillus  anthracis  is  the  anthrax  Lethal  Toxin 
(LeTx),  a  bipartite  toxin  composed  of  Protective  Antigen  and  Lethal  Factor.  Systemic 
administration  of  LeTx  to  laboratory  animals  leads  to  death  associated  with  vascular 
leakage and pulmonary edema. In this study, we investigated whether systemic exposure of 
mice to LeTx would induce gene expression changes associated with vascular/capillary 
leakage  in  lung  tissue.  We  observed  enhanced  susceptibility  of  A/J  mice  to  death  by 
systemic LeTx administration compared to the C57BL/6 strain. LeTx-induced groups of 
both  up-  and  down-regulated  genes  were  observed  in  mouse  lungs  6  h  after  systemic 
administration of wild type toxin compared to lungs of mice exposed to an inactive mutant 
form  of  the  toxin.  Lungs  of  the  less  susceptible  C57BL/6  strain  showed  80%  fewer 
differentially  expressed  genes  compared  to  lungs  of  the  more  sensitive  A/J  strain. 
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Expression of genes known to regulate vascular permeability was modulated by LeTx in 
the lungs of the more susceptible A/J strain. Unexpectedly, the largest set of genes with 
altered expression was immune specific, characterized by the up-regulation of lymphoid 
genes  and  the  down-regulation  of  myeloid  genes.  Transcripts  encoding  neutrophil 
chemoattractants, modulators of tumor regulation and angiogenesis were also differentially 
expressed in both mouse strains. These studies provide new directions for the investigation 
of vascular leakage and pulmonary edema induced by anthrax LeTx. 
Keywords: Lethal Toxin; lung; gene expression 
 
1. Introduction 
Bacillus  anthracis  is  a  spore-forming,  gram-positive  bacterium  that  is  the  causative  agent  of 
anthrax. Use of B. anthracis spores as a bioterror weapon in the United States in 2001 has renewed 
interest in exploring the mechanisms of pathogenesis and mortality induced by B. anthracis infection. 
At  least  three  forms  of  anthrax  are  known,  are  defined  by  the  route  of  spore  entry,  and  are 
characterized by differing rates of mortality. Among these, the inhalation form is the most deadly, with 
a mortality rate of at least 40% even with a high suspicion of B. anthracis and the best available 
medical care [1]. The extraordinarily high mortality of the inhalation route is likely a consequence of 
the ensuing bacteremia that is an invariable consequence of this route of infection. 
One of the major virulence factors of B. anthracis is its tripartite toxin, composed of Protective 
Antigen (PA), Lethal Factor (LF) and Edema Factor (EF) [2,3]. PA and LF combine to form Lethal 
Toxin (LeTx), while PA and EF combine to form Edema Toxin (EdTx). PA is the receptor binding 
component for both toxins. Following binding to one of its cell surface receptors, tumor endothelial 
marker 8 (TEM8) or capillary morphogenesis protein 2 (CMG2), PA is cleaved by cell-membrane 
bound furin-like proteases, resulting in 63 kD and 20 kD PA fragments. Following cleavage, the PA63 
subunits heptamerize, forming a prepore, and bind up to three molecules of LF and/or EF. The prepore 
is  then endocytosed  and,  upon acidification of the endosome, undergoes  a conformational  change 
becoming the PA pore, allowing for LF and/or EF entrance into the cytoplasm.  
As its name suggests, LeTx, a Zn
2+ metallo-protease that cleaves Mitogen Activated Protein Kinase 
Kinases (MAPKKs) [4], is lethal when delivered to laboratory animals by the systemic route [5–7]. 
The toxicity of LeTx is not considered high in comparison with other bacterial toxins [8]. However, 
during the peak of the bacteremic stage of infection, the load of B. anthracis vegetative bacteria is 
known to grow to 10
8 organisms/mL of blood, resulting in levels of secreted LF in the lethal range. 
Indeed, after a critical threshold of bacteremia is achieved, even effective sterilization of the blood by 
appropriate antibiotic treatment fails to curb mortality [9]. The capacity of B. anthracis to reach such 
high bacteremic levels is thought to be a consequence of direct effects of LF on immune cells early in 
infection. LF exposure leads to macrophage and dendritic cell death [10], inhibits T and B lymphocyte 
responsiveness [11,12], and impairs chemotaxis of neutrophils [13]. 
Systemic administration of lethal doses of LeTx to laboratory animals is known to cause blood 
vessel  leakage,  pulmonary  edema  and  cytokine-independent  vascular  collapse  [5–7];  however,  the Toxins 2011, 3  1113 
 
 
molecular mechanisms leading to these terminal events remain unclear. While a slight cytotoxic effect 
of LeTx on lung endothelial cells has been observed in vitro, endothelial cell death was not responsible 
for LeTx-induced barrier dysfunction [14]. Moreover, in vivo evidence of endothelial cell death was 
lacking in mice following administration of lethal LeTx doses [5]. 
The  hypothesis  underlying  this  study  was  that  global  gene  expression  analysis  of  a  highly 
vascularized tissue known to be affected by anthrax LeTx would reveal LeTx-specific changes in the 
expression of genes whose products are known to be associated with vascular and/or capillary leakage 
in other settings. In keeping with this hypothesis, analysis of global gene expression in lung tissue of 
mice at an early time point following systemic exposure to LeTx has resulted in the identification of 
new candidate molecular pathways that may promote LeTx-induced vascular effects. 
2. Materials and Methods 
2.1. Mice 
A/J and C57BL/6J (B6) six-week-old female mice were purchased from Jackson Laboratories (Bar 
Harbor,  ME,  USA)  and  housed  in  the  Laboratory  Animal  Resource  Center  at  Oklahoma  Medical 
Research  Foundation  (OMRF).  At  this  age,  the  body  weights  of  these  two  strains  are  
indistinguishable [15]. All mouse experiments were approved by the OMRF Institutional Animal Care 
and Use Committee. Mice were acclimated to the facility for one week prior to experimentation.  
2.2. Lethal Toxin and Mutant Toxin 
For the LD50 study, recombinant PA and LF were produced in E. coli as previously described [16,17]. 
rLF and rPA proteins were produced as amino-terminal His6-tagged proteins. Cultures of BL-21/pET15b 
(containing  LF or PA cDNA from B. anthracis) were grown in  Luria broth containing ampicillin  
(50 µg/mL) to an optical density at 600 nm (OD600) of 0.6 to 0.8. Protein expression was induced by 
addition of 1 mM isopropyl β-D-thiogalactoside (IPTG) and incubation overnight at 16 ° C. Cells were 
then  pelleted  and  disrupted  with  a  French  press.  The  lysed  cells  were  then  centrifuged,  and  the 
supernatant  was  passed  over a Ni
2+-charged column  equilibrated with  a binding buffer (Novagen, 
Gibbstown, NJ, USA). The bound fusion protein was removed with 0.5 M imidazole according to the 
manufacturer's instructions (Novagen). The eluted protein was then de-salted by passage through a  
PD-10 column (GE Healthcare, Piscataway, NJ, USA). Protein concentration was determined by a 
standard Bradford assay (Bio-Rad, Hercules, CA, USA) and stored at 4 ° C on ice. Purified PA and LF 
(20 µg) were electrophoresed in a 12.5% sodium dodecyl sulfate-polyacrylamide gel and visualized by 
Coomassie blue staining to ensure purity. For global gene expression studies, standardized, quality 
controlled preparations of PA, LF and an inactive mutant form of LF (E687C) were all purchased from 
List Biological Laboratories (Campbell, CA, USA). The manufacturer’s reported endotoxin levels in 
the  wild  type  PA  and  wild  type  LF  preparations  were  0.00069  and  0.00255  EU/µg,  respectively. 
Endotoxin levels of the mutant LF preparation were unavailable. 
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2.3. Injections and Sampling 
For  the  LD50  study,  PA  and  LF  (LeTx)  at  an  approximate  ratio  of  7:3  w:w  was  administered 
intraperitoneally in 0.2 mL/mouse PBS pH 8.0 at various concentrations to groups (N = 6 mice/group) 
of mice and deaths recorded twice daily for 7 days. For gene expression studies, PA, LF and E687C 
mutant LF were reconstituted according to the manufacturer’s instructions. Preparations of mixed PA 
plus LF (LeTx) or mixed PA plus E687C mutant LF (Mutant Tx) diluted with PBS pH 8.0 were then 
administered to groups (4 mice per group) of mice as described above except that the dosage per 
mouse was 120 µg PA + 50 µg LF for LeTx or 120 µg PA + 50 µg E687C mutant LF for Mutant Tx 
delivered in a volume of 0.25 mL per mouse. The mice were euthanized 6 hours later and lung tissue 
collected. Lung lobes from one side of the thoracic cavity were removed and placed in 1 mL of 
TRIZOL for RNA isolation. Remaining lobes were removed, fixed in formalin and paraffin blocked. 
Sections (6 µM) were stained with hematoxylin and eosin and examined for cellular infiltrates. 
2.4. RNA Isolation and evaluation of Global Gene Expression 
All surfaces were sprayed and wiped with RNaseAway to prevent RNase contamination. All 
tissues were homogenized in 1 mL of TRIZOL using a Tissue-Tearer (BioSpec Products, Bartlesville, 
OK, USA). The RNA was then isolated using the RNeasy Mini Kit from QIAGEN following the kit 
protocol. RNA quality was verified using an Agilent 2100 Bioanalyzer and concentrations determined 
by NanoDrop 1000 spectrophotometry. RNA samples were labeled using the Illumina Total Prep RNA 
Amplification Kit following manufacturer’s directions (Ambion; Austin, TX, USA). Briefly, cDNA 
was reverse transcribed from RNA after priming with T7-oligo-dT, and cRNA was synthesized in vitro 
from the T7 promoter while incorporating biotinylated UTP. cRNA was hybridized overnight to 25 K 
Illumina MouseRef-8 v. 1.1 Expression BeadChips for global gene expression. Microarray chips were 
washed to high stringency and labeled with streptavidin-Cy3 (Amersham Biosciences; Piscataway, NJ, 
USA) prior to scanning on an Illumina BeadArray Reader. 
2.5. Data Analysis 
For LD50 determinations, percent death was plotted as a function of either PA or LF concentration. 
Interpolation of the concentration of PA and LF at the 50% death point was performed in Microsoft 
Excel. LD50 values reported are based on analysis of LF plots. 
Analysis  of  the  gene  expression  data  was  conducted  using  an  internal  standard-based  method 
described  in  detail  elsewhere  [18–21].  This  method  has  been  used  recently  by  several  groups  to 
identify  differentially  expressed  genes  from  whole  genome  array  data  with  high  sensitivity  and 
specificity  [22–24].  The  method  involves  a  two-step  normalization  procedure  and  a  three-step 
Associative analysis. Briefly, the first step is defining the average and standard deviation (SD) of the 
background for each array and transforming the data such that these values are 0 and 1, respectively. 
After this transformation the gene expression data are presented in “normalized units” (NU), with  
1 NU = 1 SD of the background distribution. Based on this determination, the threshold of 3 SD above 
the mean of background is used to preliminarily distinguish between expressed and non-expressed 
genes.  In the second step of the normalization procedure, robust linear regression is  applied to a Toxins 2011, 3  1115 
 
 
homogeneous  set  of  equally  expressed  genes  to  normalize  arrays  to  each  other.  Next,  differential 
expression is determined using a three-step Associative analysis. In the first of these procedures, a 
“reference  group”  of  biologically  stable  genes  is  constructed  (comprised  of  several  thousands  of 
members) that are expressed above background but with low inherent variability as determined by an 
F-test.  This  reference  group  is  used  as  an  internal  standard  of  equity  of  expression.  The  second 
procedure in this part of the method applies a Student’s T-test using the commonly accepted threshold 
of p < 0.05 to obtain a preliminary list of differentially expressed genes that will include false positives 
determinations. The third step applies an Associative T-test in which the replicated residuals for each 
gene from the experimental group are compared with the entire set of residuals from the reference 
group of genes, defined above. Thus, the Associative T-test tests the null hypothesis that the levels of 
gene expression in the experimental group (presented as deviations from the averaged control group 
profile)  is  associated  with  a  highly  representative,  normally  distributed  set  of  residuals  of  gene 
expression values in the reference group. The Associative significance threshold is then adjusted to 
render the appearance of false positive determinations improbable [21]. Only genes that pass both the 
standard and Associative T-tests are defined as differentially expressed. The thus-defined differentially 
expressed  genes  reported  herein  exhibited  minimum  average  expression  levels  of  20  times  above 
background.  We  report  minimum  1.5  fold  differences  in  order  to  concentrate  attention  on  the 
reproducible changes of likely biologic significance. The use of 4 replicates per group in this study is 
based upon power analyses reported elsewhere [18,21]. The two-step normalization procedure and the 
Associative analysis functions are implemented in MatLab (Mathworks, MA, USA) and are available 
from  the  authors  upon  request.  These  algorithms  are  also  obtainable  from  an  R  package 
diffGeneAnalysis, available as part of Bioconductor packages [25].  
Ingenuity  Pathways  Analysis  was  used  for  classification  of  genes  into  physiologic  categories 
(Ingenuity Systems, Redwood City, CA, USA). 
3. Results 
3.1. Differential Susceptibility of A/J and C57BL/6 Mice to Death Induced by Anthrax LeTx 
Susceptibility of various inbred strains of mice to death from LeTx varies and does not correlate 
with susceptibility of their isolated macrophages to necrotic death in vitro [26]. While LeTx-induced 
necrotic death of murine macrophages is associated with polymorphisms in the Nalp1b gene [27], 
mechanisms of genetic control of mouse death by LeTx are unclear. Macrophages of both A/J and 
C57BL/6 (B6) mice are susceptible to LeTx-induced apoptosis but resistant to LeTx-induced necrosis 
in vitro [26]. To determine whether these two strains harbor differences in susceptibility to whole 
animal death by systemic administration of LeTx, we challenged groups of A/J and B6 mice with 
various doses of LeTx and recorded deaths over a 7 days period. We observed that B6 mice were less 
susceptible to LeTx-induced death than mice of the A/J strain (Figure 1). The LD50 of LeTx delivered 
in the same ratio thought to infect cells (7:3 PA:LF) was calculated as 100 µg PA/43 µg LF and 215 µg 
PA/ 92 µg LF for the A/J and B6 strains, respectively. Thus, an approximate 2-fold difference in LD50 
was  measurable  in  these  two  strains.  A  previous  study  that  found  similar  susceptibility  to  
LeTx-induced death in these two strains evaluated only a single concentration of PA and LF and 
delivered the proteins at a 1:1 ratio [26]. Toxins 2011, 3  1116 
 
 
Figure 1. Relative susceptibility of A/J and B6 mice to death by systemic exposure to 
anthrax LeTx. Percent death in groups of 6 mice per dosage point in terms of amount of LF 
delivered per mouse is shown. PA and LF were delivered i.p. at ratios of 7:3 w:w. Dosage 
ranges for each strain were determined in preliminary experiments. 
 
3.2. Lack of Obvious Pulmonary Pathology in Mice Receiving Systemic Exposure to Anthrax LeTx 
A previous pathophysiologic and histologic study of B6 and BALB/c mice systemically treated with 
LeTx demonstrated 5–10 fold increases in circulating neutrophils in both strains; however, no tissues 
revealed evidence of neutrophil margination in blood vessels even at late time points [7]. Moreover, 
lungs  remained  free  of  inflammatory  cells,  though  the  mice  suffered  from  extensive  pleural  fluid 
accumulation between 48 and 60 h post-exposure. Histologic evaluation of lung tissue sections at early 
time points (6 and 12 h post-injection) following i.p. injection of LeTx and an inactive mutant form of 
LeTx in the present study revealed normal-appearing lung tissue in both strains with no evidence of 
immune cell infiltrates and normal tissue architecture, as expected (Figure 2). 
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Figure 2. Normal histology and absence of immune cell infiltrates in mouse lungs 6 h 
following  systemic  exposure  to  anthrax  Lethal  Toxin  (LeTx)  or  inactive  mutant  toxin 
(MuTx). Representative lung sections stained with hematoxylin and eosin showing normal 
lung  architecture  and  absence  of  immune  cell  infiltrates  or  other  pathologic  findings. 
Similar results were observed 12 h following LeTx treatment. Bars mark 100 µm. 
 
3.3. LeTx-Specific Gene Expression Changes in Mouse Lung Include Genes that are Candidates for 
Mediating or Promoting Vascular Leakage and Pulmonary Edema 
All  gene  expression  data  discussed  in  this  publication  have  been  deposited  in  NCBI’s  Gene 
Expression Omnibus [28] and are accessible through GEO series accession number GSE28554 [29]. In 
total, 100 genes were differentially expressed ≥ 1.5 fold in A/J mice treated with wild type or mutant 
toxin (Table 1), while 18 genes were differentially expressed in B6 mice treated with wild type or 
mutant toxin (Table 2). Thus, significantly fewer genes (80% fewer) were modulated in the B6 strain 
compared to the A/J strain (compare Tables 1 and 2), consistent with reduced susceptibility of B6 mice 
to LeTx-induced death. Genes that were up-regulated in both strains included IGKV6-15, IGKV6-25, 
IGKV1-117,  Tet1  and  Jakmip1.  Tmem2,  a  gene  encoding  a  transmembrane  protein  of  unknown 
function, was commonly down-regulated in both strains of mice (Figure 3). 
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Table  1.  Most  significant  expression  differences  in  lungs  of  LeTx-treated  A/J  mice 
compared to Mutant Tx-treated A/J mice. A subset of significantly differentially expressed 
genes is shown based on the following criteria: (i) Average expression values must equal or 
exceed 20 Normalized Units and (ii) magnitude of differences must be ≥1.5-fold. (A) Wild 
Type LeTx (B) Mutant Tx (C) Fold change LeTx/Mutant Tx. * Average expression in 
Normalized Units. 
Genes up-Regulated in LeTx-Treated A/J Mice  Genes down-Regulated in LeTx-Treated A/J Mice 
Name         Accession   A *  B *  C  Name           Accession   A *  B *  C 
IGKV6-15         Y15976   102  41  2.5  Mfsd2a          NM_029662.2  34  92  0.37 
IGKV6-23        XM_357632.1   78  31  2.49  Slc26a4           NM_011867.3  10  24  0.43 
Cd79a         NM_007655.3  48  20  2.39  S100a9           NM_009114.2  127  282  0.45 
Blk         NM_007549.2   21  9  2.3  Ccbp2           NM_021609.3  200  439  0.45 
Fcrla        NM_145141.2  82  37  2.21  S100a8           NM_013650.2  268  577  0.46 
IGKV4-62         AJ231210   22  10  2.2  Upp1           NM_009477.3  27  58  0.47 
IGKV6-14        XM_144849.1   43  20  2.2  Gpr182          NM_007412.2  70  150  0.47 
Siglec-G        NM_172900.3  29  14  2.13  Chi3l4           NM_145126.2  39  81  0.49 
IGKV6-25         AJ235962   51  24  2.11  Gpr182          NM_007412.2  20  41  0.5 
Tubb2b        NM_023716.2  84  40  2.1  Ms4a8a           NM_022430   13  25  0.53 
IGKV6-17        XM_142951.2   44  21  2.07  P2ry13           NM_028808.3  14  27  0.53 
Cd79b        NM_008339.2  337  165  2.04  Tmem2           NM_031997.3  312  577  0.54 
Rasgrp1         NM_011246.2   162  81  2.01  Fcgr3           NM_010188.5  138  256  0.54 
Faim3        NM_026976.2  333  170  1.96  Chac1          NM_026929.4  22  41  0.55 
Sox17         NM_011441.4  252  131  1.93  Bach          NM_133348.2  25  45  0.55 
B3gnt5         NM_054052.3  35  18  1.91  Ccl6           NM_009139.3  70  122  0.57 
Stk23         NM_019684.1   47  25  1.87  Plk3           NM_013807.2  25  44  0.57 
Cd3d        NM_013487.3  136  73  1.87  Krt79          NM_146063.1   174  303  0.57 
Jakmip1        NM_178394.4  45  24  1.87  Lrg1           NM_029796.2   436  756  0.58 
IGKV1-117        XM_355772.1   44  24  1.86  Ear2           NM_007895   554  953  0.58 
Cd3e        NM_007648.4  90  50  1.79  Ccl11           NM_011330.3  19  33  0.59 
H2-Oa        NM_008206   41  23  1.78  Cxcl1           NM_008176.3  17  29  0.59 
Prkcb        NM_008855.2  70  40  1.78  Sirpb1a          NM_001002898.1  27  46  0.59 
Arl5c        NM_207231.1   45  25  1.77  Serpina3n           NM_009252.2  345  573  0.6 
Msx1         NM_010835.2  23  13  1.76  Rnase4           NM_201239   459  758  0.61 
Cd3g        NM_009850.2  97  55  1.75  Notch4           NM_010929   611  1006  0.61 
Bcl11b         NM_021399.2  46  27  1.74  Kif26b          NM_177724.3  22  36  0.61 
Scn7a        NM_009135.2  36  20  1.74  Ldb2           NM_010698   24  39  0.61 
Sidt1        NM_198034   67  39  1.73  Csf2ra           NM_009970.2  108  175  0.62 
Fcrl1        NM_178165.4  52  30  1.72  Pilra           NM_153510.3  13  21  0.62 
Gpr18         NM_182806.1   65  38  1.71  Lcn2           NM_008491.1   241  386  0.62 
Lck         NM_010693.3  87  51  1.71  Stc1           NM_009285   23  37  0.63 
Wisp2         NM_016873.2  58  34  1.7  Plaur           NM_011113.3  52  82  0.63 
Ian4         NM_031247.3  25  15  1.7  Mrc1           NM_008625.2  179  282  0.63 
Ccr7         NM_007719.2  143  86  1.67  Pfkfb4          NM_173019.5  175  274  0.64 
Satb1         NM_009122.2  193  118  1.63  Elovl1           NM_019422   59  93  0.64 
Afap1        NM_027373.2  29  18  1.63  Alox5ap           NM_009663   216  336  0.64 
Nkg7         NM_024253.4  38  24  1.63  Dcbld1           NM_025705.3  51  79  0.65 
Adamts1         NM_009621.4  22  13  1.62  Scgb3a1           NM_170727.1   27  42  0.66 
Slc7a10         NM_017394.4  102  63  1.62  Cyp2d22           NM_019823.4  157  239  0.66 
Cd69         NM_001033122.3  59  37  1.6  Tlr4           NM_021297.2  37  56  0.66 
Ddc         NM_016672.4  28  18  1.59  Bcl2a1b           NM_007534   278  421  0.66 
Nlrc3        NM_001081280  44  28  1.59  Adrb2           NM_007420.2   273  413  0.66 
Rapgef4        NM_019688.1  21  13  1.58  Dpep2           NM_176913.3   44  67  0.66 
Rgs2         NM_009061.4  22  14  1.58  Chst7           NM_021715.1   26  39  0.66 
Glcci1         NM_133236.2  21  13  1.56  Slc10a6          NM_029415.2  68  102  0.67 
Eln         NM_007925.3  215  138  1.55    Capillary Leak/Pulmonary Edema        C230071H18Rik       NM_207265.1   22  14  1.55    Lymphoid        Plec1         NM_011117   67  43  1.55    Myeloid        Tmem119        NM_146162.2  76  49  1.54    Neutrophil Recruitment        Gadd45b        NM_008655.1   43  28  1.53    Cell Structure      Nr1d1         NM_145434.3  189  124  1.53    Angiogenesis/Tumor Regulation        Tspan32        NM_020286.3  42  28  1.51    Cell Death        Tet1        NM_027384.1  24  16  1.5    Endothelial-Enriched Toxins 2011, 3  1119 
 
 
Table  2.  Most  significant  expression  differences  in  lungs  of  LeTx-treated  B6  mice 
compared to Mutant Tx-treated B6 mice. A subset of significantly differentially expressed 
genes in B6 mice is shown based on the following criteria: (i) Average expression values 
must  equal  or  exceed  20  Normalized  Units  and  (ii)  magnitude  of  differences  must  be  
≥1.5-fold. * Average expression in Normalized Units. 
Genes up-Regulated in LeTx-Treated B6 Mice  Genes down-Regulated in LeTx-Treated B6 Mice 
Name    Accession  A *  B *  C  Name      Accession  A *  B *  C 
Rrad     NM_019662.2  22  12  1.91  Fkbp5       NM_010220.3  42  81  0.52 
IGKV1-131     AJ231197   27  16  1.72  Map3k6       NM_016693   107  188  0.57 
IGKV6-15     Y15976   87  53  1.65  Itga6       NM_008397.3  14  24  0.6 
IGKV6-25     AJ235962   42  25  1.65  Nutf2       NM_026532.3  39  62  0.63 
IGKV1-117    XM_355772.1   43  27  1.62  Tmem2       NM_031997.3  20  32  0.63 
Igh-6     XM_354710.1   119  74  1.6    Lymphoid       
IGKV1-132    XM_144770.2   25  15  1.6    Neutrophil Recruitment        Tet1    NM_027384.1  24  16  1.56    Angiogenesis/Tumor Regulation     
IGKV4-61     AJ231209   41  26  1.55    Endothelial-Enriched       
Jakmip1    NM_178394.4  53  34  1.54              Ian3     NM_146167.3  23  15  1.53             
IGKV12-41    XM_355782.1   62  41  1.52             
Fkhl18     NM_010226.2  34  23  1.51             
Figure 3. Number and correspondence of early LeTx-specific gene expression changes  
in  A/J  and  C57BL/6  mouse  lungs.  Diagrams  depict  within-strain  comparisons  of  gene 
expression  in  wild  type  LeTx-  versus  Mutant  Tx-treated  mice  following  treatment. 
Differential gene expression was assessed using 4 mice per group. Only genes exhibiting  
≥1.5 fold differences were considered. 
 
At  least  eight  of  the  differentially  expressed  transcripts  are  normally  enriched  in  endothelial  
cells  [30,31].  These  included  Notch4,  Gpr182,  Adrb2,  Ccl6,  Fcgr3,  Tmem2,  Itga6,  and  Adamts1. 
Furthermore, at least three LeTx-induced gene expression changes that could promote vascular/capillary 
leakage were observed in the lungs of A/J mice. Modified expression of two endothelial-enriched 
genes,  Gpr182  and  Adrb2,  may  also  be  associated  with  vascular/capillary  leakage.  We  found  the 
expression of  Gpr182, (G-protein coupled receptor 182), a gene encoding a putative receptor for a 
49 genes 45 genes
8 genes 4genes
LeTxup-regulated LeTxdown-regulated
A/J A/J
C57BL/6 C57BL/6
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vasoactive peptide hormone that has protective effects on both endothelium [32,33] and in lungs [12], 
and Adrb2 (Adrenergic β receptor 2), a known participant in alveolar fluid clearance [34,35], to be 
down-regulated in our study. A third differentially expressed, yet up-regulated transcript that may 
influence  vascular  permeability  is  Rgs2  (Regulator  of  G-protein  Signaling  2),  which  promotes  
cGMP-mediated vascular relaxation through G-protein coupled receptors [36]. 
The modulation of genes related to cell death and apoptosis, specifically in endothelial cells, could 
also contribute to vascular/capillary leakage [37,38]. Moreover, differentially expressed genes in this 
category might reflect LeTx-mediated death of other cell types such as resident myeloid cells. In lungs 
of A/J mice treated with wild type LeTx or its inactive mutant, the differential expression of 15 genes 
associated with cell death was observed. Expression of Rasgrp1, Faim3, Sox17, Cd3e, Prkcb, Msx1, 
Lck, Satb1, Cd69 and Gadd45b was up-regulated while expression of Gpr 182, Cxcl11, Lcn2, Plaur 
and  Bcl2a1b  (B-cell  leukemia/lymphoma  2  related  protein  A1b),  the  product  of  which  protects 
macrophages from apoptosis [39], was down-regulated. 
Actins,  myosins,  microtubule  components  and  other  gene  products  that  control  endothelial  cell 
architecture are associated with vascular leakage [40] and have been observed at high levels in LeTx 
stressed endothelial cells in vitro [14]. Consistent with this, we observed that the expression of at least 
6  such  genes  was  specifically  modulated  in  A/J  lungs  by  wild  type  LeTx.  These  included  the  
up-regulation of Tubb2b, Eln, Rapgef4, Afap1, Plec1 and the down-regulation of Krt79. 
Recent  literature  linking  LeTx  with  cancer  [32,41-43]  prompted  the  categorization  of  genes 
associated with tumor regulation/angiogenesis.  In A/J mice treated with wild type LeTx,  Ms4a8a, 
P2ry13,  Plk3,  Notch4,  Plaur,  Scgb3a1,  Gadd45b,  Ccr7,  Wisp2,  Msx1  and  Adamts1  were  all 
differentially  expressed,  while  in  B6  mice  injected  with  wild  type  LeTx,  the  expression  of  Rrad, 
Fkhl18 and Map3k6 was modulated. 
Another modulated gene signature included the LeTx-mediated down-regulation of several genes 
encoding products that act as neutrophil chemoattractants. In A/J mice treated with wild type LeTx, 
these included S100a8, S100a9, Fcgr3 and Cxcl1. Additionally, Plaur, which encodes CD87/uPAR, a 
receptor that has been shown to be critical for neutrophil recruitment in vitro [44] and for neutrophil 
recruitment into mouse lungs in vivo in bacterial infection models [45,46], was down-regulated in 
LeTx-treated A/J lungs. In B6 mice, Itga6 was down-regulated by wild type LeTx. The product of this 
gene is an integrin component that is associated with chemotaxis of neutrophils [47]. One gene of this 
category, Ccr7, was up-regulated in A/J mice. 
Surprisingly, the most dominant class of regulated genes observed in this study is expressed within 
lymphocytes  and  includes  LeTx-mediated  increases  in  expression  of  several  transcripts  encoding 
canonical components of T and B lymphocyte receptors. This class of genes accounted for over 25% of 
all Le-Tx-specific gene expression changes in A/J mice and over half in B6 mice (Tables 1 and 2). 
Consistent with the well-known capacity of LeTx to mediate cell death in monocytes, macrophages 
and dendritic cells, reduced expression of a number of myeloid genes, representing 10% of the total 
number of differentially expressed genes in A/J mice, was also observed.  
Input of all differentially regulated transcripts listed in Table 1 into Ingenuity Pathways Analysis 
confirmed  significant  enrichment  of  genes  involved  in  the  processes  of  cellular  apoptosis 
(p = 1.31 ×  10
−5), cellular movement (p = 8.77 ×  10
−11), quantity of lymphocytes (p = 2.91 ×  10
−6), 
activation of lymphocytes (p = 3.11 ×  10
−6) and chemotaxis of leukocytes (2.47 ×  10
−12) (Table 3). Toxins 2011, 3  1121 
 
 
Interestingly,  this  analysis  further  revealed  significant  enrichment  in  genes  related  to  uptake  of 
arachadonic acid  (p = 1.06 ×  10
−4) and orthostatic hypotension (p = 7.29 ×  10
−4) (Table 3).  The 
number of differentially regulated genes in B6 mice (Table 2) was insufficient for Pathways analysis. 
Table 3. LeTx-induced gene expression changes in A/J mice representing processes that 
are significantly enriched in comparison to all genes evaluated. Categorization of significantly 
enriched  processes  was  determined  by  comparison  to  known  associations  within  the 
Ingenuity Knowledge Base. Statistical significance was determined using a Fisher’s exact 
test with Benjamini-Hochberg correction for multiple testing. 
 
Chemotaxis of Leukocytes  
(p = 2.47 ×  10
−12) 
Quantity of Lymphocytes  
(p = 2.91 ×  10
−6) 
Cellular Movement  
(p = 8.77 ×  10
−11) 
Cellular Apoptosis  
(p = 1.31 × 10
−5) 
Up-Regulated  Ccr7  Ccr7  Ccr7  Ccr7 
   Eln  Cd3d  Cd3e  Cd3e 
   Plec1  Cd3e  Cd69  Cd69 
   Prkcb  Cd3g  Eln  Gadd45b 
  
 
Cd69  Lck  Lck 
  
 
Lck  Plec1  Msx1 
  
 
Rasgrp1  Prkcb  Prkcb 
  
 
Satb1  Rasgrp1  Rasgrp1 
  
 
Siglecg  Tubb2b  Satb1 
  
   
Wisp2  Sox17 
  
        Down-Regulated  Ccbp2  Bcl2a1b  Adrb2  Adrb2 
 
Ccl11  Notch4  Ccbp2  Bcl2a1b 
 
Chi3l4 
 
Ccl11  Ccl11 
 
Csf2ra 
 
Ccl6  Csf2ra 
 
Ear2 
 
Chi3l4  Lcn2 
 
Plaur 
 
Csf2ra  Plaur 
 
S100a8 
 
Ear2  Serpina3n 
 
S100a9 
 
Plaur  Tlr4 
   Serpina3n 
 
S100a8 
     Tlr4 
 
S100a9 
    
   
Serpina3n 
    
   
Stc1 
    
   
Tlr4 
 
 
Activation of Lymphocytes 
(p = 3.11 ×  10
−6) 
Uptake of Arachidonic Acid 
(p = 1.06 ×  10
−4) 
Orthostatic Hypotension 
(p = 7.29 ×  10
−4) 
  Up-Regulated  Cd3d 
 
Ddc 
     Cd3e 
         Cd3g 
         Igkv1-117 
         Lck 
         Nlrc3 
         Prkcb 
         Satb1 
        
        Down-regulated  Ccl11  S100a8  Adrb2 
     Tlr4  S100a9 
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3.4. Gene Expression Differences that May Participate in Differential Susceptibility of A/J and B6 
Strains to Death by LeTx 
A large number of genes were differentially expressed between the A/J and B6 strains, consistent 
with expected genome-wide polymorphisms regulating global gene expression in these strains. As 
expected,  most  of  these  strain-determined  differences  in  gene  expression  were  irrelevant  to  LeTx 
treatment, as their expression levels were indistinguishable between the LeTx and Mutant Tx treated 
groups (data not shown). To find strain differences that may participate in the enhanced sensitivity of 
the A/J strain to death from LeTx treatment compared to the B6 strain, we identified the genes that 
exhibited both within-strain significant differential expression by wild type LeTx treatment compared 
to treatment with inactive mutant toxin (Tables 1 and 2) and also significant differential expression 
between the strains treated with wild type LeTx. This list included 12 genes: three genes associated 
with tumor regulation/angiogenesis, two lymphoid cell-expressed genes, one myeloid cell-expressed 
gene and one endothelial-enriched gene (Table 4). One gene, Elovl1, appeared twice and represents 
differential expression measurements based on two different probes with this gene on the commercial 
gene microarray employed in this study. 
Table 4. Strain differences in A/J mice (upper table) versus B6 mice (lower table) that are 
specific to LeTx treatment. Selections are listed from greatest to least magnitude of strain 
difference. *Average expression in Normalized Units. ** Selections follow the same trend 
in both strains and are therefore of less interest. 
Genes up-regulated in A/J                  
Name      Accession  A/J WT 
LeTx * 
B6 WT 
LeTx * 
A/J Mut  
Tx * 
B6 Mut 
Tx * 
A/J WT/  
B6 WT 
A/J Mut/  
B6 Mut 
Msx1 **      NM_010835.2  23  11  13  7  2.06  1.77 
Slc7a10      NM_017394.4  102  59  63  57  1.74  1.10 
Ddc      NM_016672.4  28  18  18  19  1.61  0.93 
Adamts1      NM_009621.4  22  14  13  11  1.59  1.23 
Bcl11b      NM_021399.2  46  29  27  23  1.58  1.16 
                   
 
        
Genes up-regulated in B6                     
Name   
  Accession  A/J WT 
LeTx * 
B6 WT 
LeTx * 
A/J Mut  
Tx * 
B6 Mut 
Tx* 
B6 WT/  
AJ WT 
B6 Mut/  
AJ Mut 
Scgb3a1      NM_170727.1   27  65  42  43  2.38  1.04 
Elovl1      NM_019422   59  140  93  138  2.36  1.49 
Elovl1      NM_019422   116  248  171  216  2.15  1.26 
Fkbp5 **      NM_010220.3  22  42  43  81  1.88  1.89 
P2ry13      NM_028808.3  14  26  27  36  1.84  1.32 
Ian3 **      NM_146167.3  15  23  8  15  1.59  1.87 
Pfkfb4      NM_173019.5  175  272  274  295  1.55  1.08 
Alox5ap      NM_009663   216  330  336  368  1.53  1.10 
   
 
          Lymphoid 
 
   
 
          Myeloid 
   
   
 
          Angiogenesis/Tumor Regulation 
   
 
          Endothelial-Enriched 
4. Discussion 
Central features of both B. anthracis- and LeTx-induced animal death are vascular leakage and 
pulmonary  edema.  One  important  mechanism  of  LeTx-induced  vascular  leakage  may  be  direct 
induction of endothelial cell death [37]. However, reports that LeTx-induced endothelial cell death is Toxins 2011, 3  1123 
 
 
inefficient  [38]  and  absence  of  measurable  endothelial  cell  death  in  mice  receiving  LeTx  doses 
sufficient to induce animal death [5] suggest that additional mechanisms may operate to promote the 
vascular effects of this toxin. In this study we evaluated early effects of LeTx in highly vascularized 
lung  tissue  in  order  to  identify  transcriptional  changes  pointing  to  new  potential  mechanisms  of  
LeTx-induced vascular effects including vascular leakage and pulmonary edema. Although this study 
was designed to identify the earliest LeTx-induced gene expression changes, other transcripts that are 
modulated at late time points may also be important in pathogenesis. Nevertheless, at least 8 of the 
identified differentially expressed transcripts are normally enriched in endothelial cells (Tables 1, 2 
and 4), including Gpr182 and Adrb2, discussed in more detail below. 
Though not an endothelial-specific gene per se, Rgs2 is expressed in endothelial cells and was 
specifically induced by LeTx. Rgs2 encodes Regulator of G-protein Signaling 2, a GTPase activating 
protein (GAP) critical for negative regulation of G (q) alpha receptors and control of vascular tone and 
blood pressure. Previously, the up-regulation of Rgs2 was observed in the hearts of Swiss Webster 
mice  48  h  post-inhalational  Ames  spore  challenge  [48].  We  observed  significant  up-regulation  of  
Rgs2 in A/J mice due to LeTx treatment alone. Mice deficient in this gene exhibit hypertension and 
decreased cGMP-mediated vascular relaxation [36,49], indicating that  modulating vascular smooth 
muscle  homeostasis  is  a  unique  role  for  this  GAP.  Elevated  expression  of  Rgs2  would  thus  be 
predicted to result in vascular relaxation and may contribute to LeTx-mediated animal death since 
lowered mean arterial blood pressure occurs early following LeTx infusion and predicts non-survivors 
of systemic LeTx exposure [6,50]. Interestingly, Rgs2 was originally cloned as an early response gene 
up-regulated in activated T cells [51]. Given the lymphocyte gene signature also observed in this study, 
it  is  also  possible  that elevated  Rgs2  could  be  occurring  primarily  in  T  lymphocytes  (see  further 
discussion  below).  Further  studies  to  assess  expression  of  Rgs2  in  isolated  vascular  tissue  from  
LeTx-treated animals will be needed to clarify this point. An interesting study would be to determine 
whether Rgs2 deficient mice exhibit enhanced resistance to LeTx-mediated death. 
Another  important  LeTx-mediated  expression  change  observed  was  down-regulation  of  the 
endothelial-enriched gene Gpr182 encoding the adrenomedullin receptor (ADMR). Adrenomedullin is 
a  potent  blood  vessel-secreted  vasoactive  peptide  hormone  [33]  that  can  suppress  apoptosis  of 
endothelial cells [52] and prevent bleomycin-induced lung injury when administered intratracheally to 
mice [53]. Interestingly, a previous study found dramatic up-regulation of Adm, the gene coding for 
adrenomedullin, in the hearts of Ames spore challenged mice [48]. Whether the Gpr182 gene product 
is a bona-fide receptor for adrenomedullin is controversial, however. Binding of adrenomedullin to 
COS-7 cells transfected with rat or human ADMR was not detectable [54]; however, siRNA-mediated 
silencing of ADMR expression in both HUVEC and mouse lung endothelial cells demonstrated that 
autocrine effects of adrenomedullin in these cells were mediated through ADMR [55].  
Expression of a second endothelial-enriched gene, adrenergic β receptor 2 (Adrb2) was modulated 
by LeTx treatment. Adrenergic β receptor 2 agonists have been demonstrated to participate in up-regulation 
of active Na
+ transport in vitro [56]. More recently, up-regulation of alveolar fluid clearance due to 
increased active Na
+ transport has been demonstrated in vivo [35,57]. Additionally, C57BL/6 Adrb2 
knockout mice have severely impaired ability to clear alveolar fluid  when compared to wild type  
mice [34]. In our study, this gene was significantly down-regulated in A/J mice treated with LeTx; 
supporting that proper Adrb2 function could be necessary for clearance of LeTx associated pulmonary Toxins 2011, 3  1124 
 
 
edema. Further studies, such as exploring the effects of adrenergic β receptor 2 agonists on LeTx 
treated mice or evaluation of Adrb2 deficient mice for enhanced susceptibility to LeTx-mediated death, 
are needed to investigate this possibility. 
Our study also revealed a group of genes associated with cellular structure. These genes code for 
tubulin,  actin,  keratin,  and  other  intermediate  filaments  that  are  involved  with  both  inter-  and  
intra-cellular architecture and may contribute to vascular leakage in the lungs [58]. Consistent with a 
previous  study  that  observed  the  formation  of  actin  stress  fibers  upon  LeTx  treatment  [14],  we 
observed  the  up-regulation  of  actin  filament  associating  protein  1,  or  Afap1.  Additionally,  the  
down-regulation of Krt79, which codes for keratin, a component of desmosomes, is consistent with the 
possibility that the disruption of intercellular junctions may lead to vascular leakage.  
While the primary goal of this study was to identify new candidate pathways that may promote 
vascular leakage and pulmonary edema in LeTx-treated mice, additional groups of genes for other 
processes were also identified. One such identified process that was enriched among differentially 
expressed genes in A/J mice was cell death. Although endothelial cell death may not be the major 
cause  of  vascular/capillary  leakage,  cell  death  in  other  cell  types  due  to  exposure  to  LeTx  may 
contribute to increased B. anthracis virulence. In this study we observed a down-regulated myeloid 
gene signature in A/J mice treated with LeTx. Since LeTx is known to kill macrophages [59,60] and 
host myeloid cell death may be essential for successful B. anthracis infection [61], this myeloid related 
gene signature is of interest. Genes expressed specifically in macrophages (Mrc1, Csf2ra, Ccl6, and 
Sirpb1a), neutrophils (Ccl6, Sirpb1a, and Lcn2) and other myeloid cells were observed.  
Products of another observed group of differentially expressed immune-related genes participate in 
neutrophil chemoattraction. Although neutrophilia is induced in the circulation by LeTx, margination 
of neutrophils into tissues is conspicuously absent in such animals [7]. Barson et al. observed the 
suppression of chemokine producing gene expression in vitro after 2 hours of LeTx exposure [62]. 
Furthermore, LeTx has been shown to inhibit neutrophil chemotaxis in a direct manner by a process 
that  impairs  actin filament  assembly  [13]. The  present  study suggests that  LeTx may  also  impair 
neutrophil chemotaxis in whole lung tissue through additional mechanisms including transcriptional 
inhibition  of  neutrophil  chemoattractants  and  transcriptional  down-regulation  of  urokinase-type 
plasminogen activator (CD87/uPAR), encoded by Plaur. This gene product promotes trans-endothelial 
migration  of  neutrophils  [44].  Mice  deficient  in  uPAR  demonstrated  severely  impaired  neutrophil 
migration  into  lungs  and  impaired  host  defense  against  pulmonary  infection  with  Psuedomonas 
aeruginosa [46] and Pneumococcal pneumonia [45].  
Interestingly, a group of 15 differentially expressed genes, 12 in A/J mice and 3 in B6 mice, related 
to  tumor  regulation/angiogenesis  was  observed.  Considering  the  unique  cytoplasmic  translocation 
method  utilized  by  LF  via  PA  [41],  the  specificity  of  the  PA/receptor  interaction  and  innate  
anti-angiogenic properties of LF, and the over-expression of the anthrax toxin receptor TEM-8 in 
tumor endothelium [63], it is not surprising that some investigators have begun to explore the use of 
LeTx as a method of tumor therapy [32,42,43]. Disrupting angiogenesis is a possible means by which 
LeTx achieves tumor regulation. The down-regulation of pro-angiogenic genes in our study such as 
Gpr182 [55], P2ry13 [64] and Plaur [65] is consistent with this.  
Unexpectedly, the most prominent  LeTx-induced differentially  expressed gene signature, which 
was  found  in  both  A/J  and  B6  mice,  involved  enhanced  expression  of  multiple  lymphoid  genes, Toxins 2011, 3  1125 
 
 
including genes encoding the canonical antigen receptors of both T and B lymphocytes. Ingenuity 
Pathways Analysis revealed significant enrichment of differentially expressed genes suggesting both 
quantity and activation of lymphocytes. Our histologic analysis of lung tissue revealed lungs devoid of 
lymphocytic infiltrates, in agreement with other studies demonstrating lack of immune cell infiltrates 
in lungs even at late time points following systemic LeTx exposure [52]. Because 6 h is an insufficient 
length of time for T or B cell proliferation in response to any stimulus, these prominent transcriptional 
changes  could  either  represent  a  prelude  to  proliferation  of  lymphocytes  already  present  in  the 
lungs/lung  vasculature  or  LeTx-mediated  lymphocyte  activation.  Indeed,  CD69  transcripts  were 
elevated in LeTx-treated lungs of A/J mice at this early time point. In contrast, several groups have 
demonstrated  that  LeTx  instead  impairs  lymphocyte  proliferation  and  activation  [11,12,66,67]. 
However, all of these studies either examined responses of isolated lymphocytes in vitro or examined 
restimulation of lymphocytes previously exposed to LeTx. One interesting study demonstrated that 
LeTx has a mitogenic effect on T cells, resulting in their proliferation [68]. This mitogenic effect was 
shown to be mediated indirectly through a soluble factor secreted by monocytes, and the proliferating 
cells had not been stimulated through the T cell receptor. The effect could not have been mediated by 
endotoxin  contamination  of  LeTx  components  because  T  cell  proliferation  did  not  occur  in  the 
presence of PA or LF alone and also failed to occur in the presence of PA plus an inactive mutant of 
LF.  The  results  of  the  present  study  lead  to  speculation  that  a  similar  mitogenic  effect  may  be 
occurring in vivo in LeTx-treated mice, resulting in initial LeTx-mediated lymphocyte activation. Such 
an abnormal activation event could easily lead to an anergic state, rendering lymphocytes unresponsive 
to  further  stimulation.  Interestingly,  pharmacological  treatment  with  interleukin-2  (IL-2)  causes  a 
vascular leakage syndrome [69,70], and rapid, systemic mitogenic T cell proliferation may well be 
accompanied by a burst of systemic IL-2. 
5. Conclusions 
This study has identified new directions for the investigation of LeTx-induced vascular effects, 
pulmonary edema and animal death. Further investigation of vascular G (q) alpha receptors, impaired 
adrenomedullin-mediated  vascular  protection,  adrenergic  β  receptor  2-mediated  pulmonary  fluid 
clearance,  and  mitogenic  T  lymphocyte  activation  as  possible  mechanistic  pathways  promoting  
LeTx-induced death are warranted. 
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